Rebecca Araujo

DocwireNews

DocWire News sat down with Natalie Callander, MD, professor and director of the Myeloma Clinical Program at the University of Wisconsin Carbone Cancer Center, about B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM), and data on the benefits of this agent for the treatment of relapsed/refractory disease.DocWire News: BCMA is a target of interest for MM. What makes BCMA CAR T cell therapies different from other CAR Ts for this disease?Dr. Callander: CART T, chimeric antigen receptor T cells, are basically a concept of reprogramming a patient&rsquo;s own T cells to go after various targets. Probably, the first one that was really investigated is one called CD19 and that&rsquo;s actually displayed on B cells of all types. It was initially investigated in MM, but it appeared to be a relatively poor target that cells would lose CD19 and perhaps not all myeloma cells were displaying that. BCMA is more reliably expressed on plasma cells in myeloma cells; and again, the concentration of BCMA antigen on the surface of myeloma cells seems to increase as patients become more refractory. Because it&rsquo;s also pretty much limited to plasma cells, that means that there are fewer off target effects, which is, again, a very nice property of these kinds of drugs. You would like to just target the myeloma cells and not other drugs or not other types of cells. BCMA fits that purpose.&nbsp;DW: Do BCMA CAR T cells appear to be a beneficial therapy for patients with relapsed/refractory MM?Dr. Callander: Well, I think that we&rsquo;ve got some great data, both from the KarMMA study, as well as the CARTITUDE study. These are a slightly different CAR T products. Both of them have had very high response rates. The CARTITUDE trial was updated at [the American Society of Hematology (ASH) 2020 Annual Meeting] recently and showed a 97% response rate, which is pretty amazing and people who&rsquo;ve had an average of five different types of treatment. I think that these therapies really are going to be used widely. There is going to be a limitation initially that there has to be some expertise in the facilities that are administrating CAR T just so they&rsquo;re familiar with some of the side effects. Some of the side effects vary a little bit in timing, depending on the different CAR T products. But again, one of the patient advantages receiving these types of treatments is they then have a period of time when they&rsquo;re actually off therapy, which many, many, many patients really enjoy.I think with the kind of response rates and the duration of response, which seems to be quite good, particularly in those patients who obtain a complete remission, I think that these are going to be probably sought after as soon as they&rsquo;re FDA approved.I think one thing that we don&rsquo;t know, just thinking about BCMA and different drugs that are out there. We do have belantamab, that&rsquo;s the only drug commercially available right now that targets BCMA. There are these bio-specific engagers that target BCMA; then, there&rsquo;s CAR T. One thing that we don&rsquo;t know yet is how you sequence this. If you have had one BCMA therapy and it stops working, could you move to another? Or is there sort of an optimal way you move through these over time?

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Dr. Callander: BCMA CAR T Cell Therapy for Relapsed/Refractory MM

Oncology

DocWire News sat down with Natalie Callander, MD, professor and director of the Myeloma Clinical Program at the University of Wisconsin Carbone Cancer Center, about B-cell ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe